RT Journal Article
SR Electronic
T1 SARS-CoV-2 Seroprevalence in Relation to Timing of Symptoms
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.02.20166876
DO 10.1101/2020.08.02.20166876
A1 Joseph E. Ebinger
A1 Gregory J. Botwin
A1 Christine M. Albert
A1 Mona Alotaibi
A1 Moshe Arditi
A1 Anders H. Berg
A1 Aleksandra Binek
A1 Patrick Botting
A1 Justyna Fert-Bober
A1 Jane C. Figueiredo
A1 Jonathan D. Grein
A1 Wohaib Hasan
A1 Mir Henglin
A1 Shehnaz K. Hussain
A1 Mohit Jain
A1 Sandy Joung
A1 Michael Karin
A1 Elizabeth H. Kim
A1 Dalin Li
A1 Yunxian Liu
A1 Eric Luong
A1 Dermot P.B. McGovern
A1 Akil Merchant
A1 Noah Merin
A1 Peggy B. Miles
A1 Trevor-Trung Nguyen
A1 Koen Raedschelders
A1 Mohamad A. Rashid
A1 Celine E. Riera
A1 Richard V. Riggs
A1 Sonia Sharma
A1 Kimia Sobhani
A1 Sarah Sternbach
A1 Nancy Sun
A1 Warren G. Tourtellotte
A1 Jennifer E. Van Eyk
A1 Jonathan G. Braun
A1 Susan Cheng
YR 2020
UL http://medrxiv.org/content/early/2020/08/04/2020.08.02.20166876.abstract
AB Of individuals with SARS-CoV-2 IgG antibody testing performed, those who contemporaneously experienced a cluster of Covid-19 relevant symptoms in the 1-2 months preceding the antibody assay were more likely to test positive whereas those who experienced the symptom clustering in the prior 3-6 months were more likely to test negative. These findings suggest that antibodies likely wane over a period of months, particularly in relation to the timing of symptoms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by Cedars Sinai Medical Center and the Erika J. Glazer Family Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study protocols were approved by the Cedars Sinai institutional review board and all participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from Cedars-Sinai Medical Center, upon reasonable request. The data are not publicly available due to the contents including information that could compromise research participant privacy/consent.